Pharmaceutical

Eli Lilly will give small biotechnology companies a chance to use artificial intelligence models trained on years of the pharmaceutical company’s rese...

New partnership aims to fast-track mRNA therapies from lab to clinic New partnership aims to fast-track mRNA therapies from lab to clinic

First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex

Chronic inflammatory demyelinating polyneuropathy, or CIDP, is a rare autoimmune disease that can cause severe numbness, weakness and disability. In a...

By nailing the primary endpoint in a phase 3 trial, Eli Lilly's Bruton tyrosine kinase (BTK) inhibitor Jaypirca has come one step closer to reaching a...

The Trump administration has excluded generic drugs from a baseline 15% tariff on imports from Japan under a new trade deal between the two countries....

British biotechnology company NRG Therapeutics on Monday said it raised £50 million, or about $67 million, to advance its lead experimental medicine f...

Dive Brief: Rapport Therapeutics’ market value doubled on Monday after the neurology-focused drugmaker unveiled mid-stage study results for an experim...

Combining Summit Therapeutics and Akeso’s closely watched cancer drug with chemotherapy didn’t help people with lung cancer live longer than chemo alo...

Dive Brief: Pfizer and partner BioNTech said Monday their updated COVID-19 booster spurred strong immune responses against currently circulating coron...